Metrics as of 10/14/2026, 12:23 PM (Berlin time), refresh in progress.
Nuvalent Stock
Nuvalent, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- James R. Porter
- Employees
- 234
- Market cap
- $9.1 B
- IPO
- 29/07/2021
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company was established in 2017 and is based in Cambridge, Massachusetts. Nuvalent's pipeline features two prominent drug candidates. One of these assets is NVL-520, a…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Nuvalent stock: price history
1D
+0.0%
1W
+0.0%
1M
+0.4%
6M
+17.0%
YTD
+23.2%
1Y
+50.3%
2Y
+57.0%
5Y
–
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~1% weaker price swings than usual
Ask the agents about Nuvalent
Analyst assessment of Nuvalent
PRICE TARGET LOW
US$122.85
CONSENSUS
US$127.32
MEDIAN
US$124.00
PRICE TARGET HIGH
US$165.00
0
STRONG BUY
8
BUY
11
HOLD
0
SELL
0
STRONG SELL
19
TOTAL · Hold
As of: 24/06/2026
Nuvalent stock metrics
P/E
-20.46
P/B
8.3
EV/EBITDA
-26.84
RETURN ON EQUITY
-9.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
31/03/2026
Free float & liquidity
FREE FLOAT
66.6%
FLOAT SHARES
49,108,264
AVG. DAILY VOLUME (30D)
3,897,120
Insider transactions (SEC)
Flynn James E
Flynn James E
Flynn James E
Flynn James E
Flynn James E
Institutional holders
Comparable stocks
Frequently asked questions about Nuvalent stock
What does Nuvalent do?
Nuvalent, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is James R. Porter, the company employs around 234 people.
The IPO was on 29/07/2021; the stock trades on NASDAQ under the ticker NUVL.
What do analysts say about Nuvalent stock?
19 analysts rate the stock, the consensus is Hold (as of 24/06/2026).
The average price target is US$127.32, ranging from US$122.85 to US$165.00, with a median of US$124.00.
This is an external assessment, not a statement by Market Jury.
When does Nuvalent report next?
Around past earnings, price swings were roughly -1% stronger than usual.
Does Nuvalent pay a dividend?
No, Nuvalent currently does not pay a dividend.
Which stocks are comparable to Nuvalent?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Nuvalent stock analyzed?
Clicking "Analyze stock" lets five strategies assess Nuvalent against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.